TY - JOUR
T1 - Inflammatory Pathways in Psychiatric Disorders
T2 - the Case of Schizophrenia and Depression
AU - Feng, Tami
AU - Tripathi, Ashutosh
AU - Pillai, Anilkumar
N1 - Funding Information:
This work was supported by US National Institute of Health/ National Institute of Mental Health (NIMH) grants (MH120876 and MH121959) and the Merit Review Award (BX004758) from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development to AP. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. Copyright Code Availability
Publisher Copyright:
© 2020, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Purpose of Review: A better understanding of the key molecules/pathways underlying the pathophysiology of depression and schizophrenia may contribute to novel therapeutic strategies. In this review, we have discussed the recent developments on the role of inflammatory pathways in the pathogenesis of depression and schizophrenia. Recent Findings: Inflammation is an innate immune response that can be triggered by various factors, including pathogens, stress, and injury. Under normal conditions, the inflammatory responses quiet after pathogen clearance and tissue repair. However, abnormal long-term or chronic inflammation can lead to damaging effects. Accumulating evidence suggest that dysregulated inflammation is linked to the pathogenesis of neuropsychiatric disorders. In this review, we have discussed the roles of complement system, infiltration of peripheral immune cells into the central nervous system (CNS), the gut-brain axis, and the kynurenine pathway in depression and schizophrenia. Summary: There is a large body of compelling evidence on the role of inflammatory pathways in depression and schizophrenia. Although most of these findings show their roles in the pathophysiology of the above disorders, additional studies are warranted to investigate the therapeutic potential of various immune signaling targets discussed in this article.
AB - Purpose of Review: A better understanding of the key molecules/pathways underlying the pathophysiology of depression and schizophrenia may contribute to novel therapeutic strategies. In this review, we have discussed the recent developments on the role of inflammatory pathways in the pathogenesis of depression and schizophrenia. Recent Findings: Inflammation is an innate immune response that can be triggered by various factors, including pathogens, stress, and injury. Under normal conditions, the inflammatory responses quiet after pathogen clearance and tissue repair. However, abnormal long-term or chronic inflammation can lead to damaging effects. Accumulating evidence suggest that dysregulated inflammation is linked to the pathogenesis of neuropsychiatric disorders. In this review, we have discussed the roles of complement system, infiltration of peripheral immune cells into the central nervous system (CNS), the gut-brain axis, and the kynurenine pathway in depression and schizophrenia. Summary: There is a large body of compelling evidence on the role of inflammatory pathways in depression and schizophrenia. Although most of these findings show their roles in the pathophysiology of the above disorders, additional studies are warranted to investigate the therapeutic potential of various immune signaling targets discussed in this article.
KW - Complement system
KW - Depression
KW - Gut-brain axis and kynurenine pathway
KW - Infiltration
KW - Inflammation
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85090083385&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090083385&partnerID=8YFLogxK
U2 - 10.1007/s40473-020-00207-4
DO - 10.1007/s40473-020-00207-4
M3 - Review article
AN - SCOPUS:85090083385
SN - 2196-2979
VL - 7
SP - 128
EP - 138
JO - Current Behavioral Neuroscience Reports
JF - Current Behavioral Neuroscience Reports
IS - 3
ER -